The latest trading day saw Recursion Pharmaceuticals (RXRX) settling at $3.18, representing a -3.34% change from its previous close.

Everyone is racing to point powerful AI models at drug discovery. A growing camp argues the real prize is the layer beneath the models — the connected biological knowledge they reason over — and that ...

CBSE Class 9 Maths Syllabus 2026-27 PDF is now available for download. Check the latest chapter-wise syllabus, unit-wise weightage, course structure, and direct PDF download link for the 2026-27 ...

Spread the love“`html Understanding how to create a neural network can be a game-changer in the fields of artificial intelligence and machine learning. As industries increasingly rely on data-driven ...

When artificial intelligence runs out of human thought, it doesn't just get dumber; it loses the ability to recognize the difference.

Every machine that ever mattered was built by a human hand. Someone drew the blueprint, cut the steel, or wrote the code, then signed off before it shipped. We argue about who gets rich and whose job ...

The companies at the frontier of artificial intelligence should be ready to slow down, one of the fastest-moving among them says. Anthropic, the maker of the Claude chatbot, has claimed AI systems may ...

Recursion Pharmaceuticals is trying to solve a serious problem. Even with technological improvements, the time and costs required to develop brand-new drugs have increased in recent decades. It can ...

Recursive Superintelligence has raised $650 million at a $4.65 billion valuation in a funding round led by GV and Greycroft, according to the company. The round also included participation from AMD ...

Recursive Superintelligence Inc., a startup that hopes to develop self-improving artificial intelligence models, launched today with $650 million in funding. Alphabet Inc.’s GV fund and Greycroft led ...

This voice experience is generated by AI. Learn more. This voice experience is generated by AI. Learn more. logos of OpenAI There’s interesting news coming from Sam Altman’s empire, a firm known for ...